Scarica l'app Stockscreener
39.71
4.17%
-1.73
Dopo l'orario di chiusura:
39.95
0.24
+0.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Ignore Nektar Therapeutics stock in 2026 and load up on this one instead - MSN
Nektar leaps a third on abuse-deterrent analgesic data - The Pharma Letter
Why Nektar Therapeutics stock remains on watchlists2025 Macro Impact & Advanced Swing Trade Entry Alerts - ulpravda.ru
Can Nektar Therapeutics stock sustain institutional interestJuly 2025 Earnings & Accurate Intraday Trading Signals - ulpravda.ru
Why analysts remain bullish on Nektar Therapeutics stockTrend Reversal & Weekly High Return Stock Forecasts - ulpravda.ru
Is Nektar Therapeutics stock a dividend growth opportunity2025 Trade Ideas & Precise Trade Entry Recommendations - ulpravda.ru
Is Nektar Therapeutics stock a buy in volatile marketsJuly 2025 Market Mood & High Accuracy Trade Alerts - ulpravda.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar TherapeuticsNKTR - PR Newswire
Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Yahoo Finance
Portfolio Shifts: Why Nektar Therapeutics ITH0 stock trades below fair valueJuly 2025 Trends & Expert Approved Trade Ideas - moha.gov.vn
How The Narrative Around Nektar Therapeutics (NKTR) Is Shifting With Rezpeg Data And Litigation Risks - Yahoo Finance
Will Nektar Therapeutics (ITH0) stock outperform energy sector in 20252026 world cup usa national team round of 16 goalkeepers set piece tactics group prediction breakdown - Улправда
Nektar Therapeutics Too Risky? This Biotech Stock Offers a Safer Bet - NAI500
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - AOL.com
New anxiety medications are in the pipeline for 2026 - AOL.com
FDA Leadership Stability Urged as Rare Disease Drug Approval Policies Expected to Show Results by 2026 - geneonline.com
Nektar Therapeutics: Can a Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
What drives Nektar Therapeutics stock priceFinancial Sector Performance & Free Unlock Portfolio Growth - earlytimes.in
How Nektar Therapeutics stock reacts to global recession fearsGrowth vs. Value Investing & Optimize Entry & Exit With Smart Signals - bollywoodhelpline.com
Drugs to Watch in 2026 - Dermatology Times
Nektar Therapeutics Stock Analysis and ForecastStock Screening Results & Outstanding Return Portfolio - earlytimes.in
Moody Aldrich Partners LLC Buys 28,304 Shares of Nektar Therapeutics $NKTR - MarketBeat
Top 10 skin disorder stories of 2025 - Healio
Simplify Asset Management Inc. Buys 35,176 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Wrap: Why Nektar Therapeutics stock could rally in 2025Earnings Growth Summary & Risk Adjusted Buy/Sell Alerts - moha.gov.vn
Dermatology Times 2025 Year in Review: Atopic Dermatitis - Dermatology Times
Nektar Therapeutics Shares Rise After Positive Asthma Data in Atopic Dermatitis Patients - MSN
Brain Implants for Mental Health and Chinese Competition Expected to Shape BCI Advancements by 2026 - geneonline.com
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Nektar Therapeutics (NKTR) price target increased by 14.31% to 109.43 - MSN
More Unpleasant Surprises Could Be In Store For Nektar Therapeutics' (NASDAQ:NKTR) Shares After Tumbling 25% - simplywall.st
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Nektar Therapeutics (NKTR) CEO reports RSU and stock option grants - Stock Titan
Published on: 2025-12-23 18:23:01 - moha.gov.vn
Nektar Therapeutics announces phase 2b trial results - MSN
Atopic Dermatitis in 2025: Year in Review - HCPLive
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data - Benzinga
Transformative Advances This Year and Beyond - Dermatology Times
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) - Insider Monkey
Is Nektar Therapeutics (ITH0) stock ideal for retirement investors2025 Trading Volume Trends & Accurate Buy Signal Alerts - ulpravda.ru
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions - Seeking Alpha
Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows - Yahoo Finance
Machine Learning Tool vConTACT3 Developed to Enhance Global Virus Classification - geneonline.com
Is Nektar Therapeutics stock resilient to inflationMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - Улправда
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN
Assessing Nektar Therapeutics (NKTR) Valuation After a Volatile Year and Recent Share Price Pullback - simplywall.st
Nektar Therapeutics Q3 2025 Earnings Preview - MSN
Oppenheimer maintains Outperform rating on Q32 Bio stock at $20 target - Investing.com
Nektar Therapeutics announces top-line results from alopecia areata study - PMLiVE
Nektar Therapeutics Price Target Raised to $118.00/Share From $100.00 by BTIG - 富途牛牛
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):